Nick Opich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First-ever set of professional guidelines informed by clinical research and expert consensus will set benchmarks for practitioners in an emerging field...

Mydecine Innovations Group, Inc., is pleased to announce that its subsidiary Mindleap Health a digital health platform and the world’s-first telemedicine application purpose-built for the psychedelic medicine industry, has filed a provisional patent for its technology platform in both The United States Patent and Trademark Office and the Canadian Intellectual Property Office. “As our company continues to innovate … Mydecine Innovations Group, Inc., ( CSE:MYCO ) ( OTC:MYCOF ) ( FSE:0NFA ) (“Mydecine” or the “Company”) is pleased to announce that its subsidiary Mindleap Health (�...

What: Om of Medicine, one of the leading cannabis provisioning centers serving the Ann Arbor community, is hosting a Meet & Greet with Viola Brands CEO and NBA legend, Al Harrington. Where: 111 S. Main Street, 1st Floor Ann Arbor, MI 48104 When: February 16, 2021 at 4:00-6:00 PM ET Who: Viola Brands CEO and NBA legend, Al Harrington will be onsite along with Om of Medicine Founder and EVP of Operations at Mission Dispensaries Mark Passerini. Both Mark & Al will be available to meet with attendees and press at the socially distant meet and greet. Due to capacity restrictions, Om of Medicine ...

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management, Ltd., to the Company’s Board of Directors. Josh Bartch, Chairman and CEO of Mydecine, stated, “The Board of Directors welcomes Ms. Josephine Wu … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a...

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange . Final approval is subject to the Company fulfilling all of NEO’s listing requirements. With the impending … Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Compa...